Summary: Researchers reveal how targeting transcranial magnetic stimulation (TMS) could enhance treatment for depression. The study identified an electrophysiological marker that could predict TMS efficacy and guide personalized therapy. By optimizing the stimulation site and coil angle, treatment outcomes may improve. These findings offer hope for better, tailored TMS therapies in the future.
Key Facts:
- Predictive Biomarker: An electrophysiological marker could predict TMS treatment success.
- Personalized Treatment: Optimizing stimulation site and coil angle enhances TMS efficacy.
- Research Potential: Findings pave the way for more effective, individualized TMS therapies.
Source: University of Helsinki
Not all patients with depression respond to medication. Two recently published studies provide additional information on how an alternative treatment, transcranial magnetic stimulation (TMS), could be further enhanced. TMS differs from electroconvulsive therapy (ECT), which is also used to treat depression.
Researchers from the University of Helsinki and Stanford University investigated which factors in targeting TMS influence the brain’s elect
rical responses. They examined the behavior of a specific electrophysiological marker. This marker could potentially be used as a biomarker in the future to measure the efficacy of TMS treatment and thus help target and tailor the therapy.
“Magnetic stimulation is an effective treatment for patients whose depression is not alleviated by medication. However, currently, about half of these patients do not receive significant help from TMS.
“The biomarker we studied may help predict who will benefit from the therapy. In the future, it may also be possible to tailor the treatment individually,” says postdoctoral researcher Juha Gogulski from Stanford, University of Helsinki and Aalto University.
Individual optimization is worthwhile
The first study addressed an electrophysiological marker that describes cortical excitability and the sources of error affecting its measurement. Researchers studied healthy subjects to determine how magnetic stimulation targeted to the prefrontal cortex and the angle of the stimulation coil affected cortical excitability, that is, the responses measured on an electroencephalogram (EEG) immediately after the stimulation pulse.
“The results showed that targeting of the stimulation coil in different parts of the prefrontal cortex significantly affected the quality of electrical responses. Additionally, we found indications that individual optimization of the stimulation site and coil angle may further improve the quality of this metric,” says Gogulski.
The second study dealt with the reliability of the same electrophysiological marker in the prefrontal cortex. The study revealed that the most significant factor affecting reliability was the stimulation site.
“Before we can develop personalized TMS therapy, we must ensure that the excitability of the prefrontal cortex can be measured as accurately as possible in individual patients to be able to monitor how TMS treatment changes brain excitability. Determining reliability is also essential before this type of biomarker can be applied clinically,” says Gogulski.
Potential benefits are significant, more research needed
Magnetic stimulation already helps some people with depression, but according to Gogulski, the effectiveness of TMS therapy varies between individuals. More precisely tailored treatment might improve outcomes.
“There are many possible factors in TMS therapy that could be used for individual tailoring, such as the stimulation site, the number and frequency of pulses, the intensity of the stimulation, and the number of treatment sessions. The side effects of TMS therapy are minimal, with the most common being a temporary, mild headache.”
According to Gogulski, what makes the new studies significant is that this detailed systematic mapping of the electrical responses of the prefrontal cortex and their reliability has not been done before.
The researchers hope that in the future, the effectiveness of TMS therapy can be monitored by measuring the brain’s electrical responses during treatment. Based on these measurements, it might be possible to fine-tune the stimulation if necessary, even during the treatment.
“The results of both studies will be utilized in the future when designing individual brain stimulation therapies based on electrical biomarkers. However, more research is needed before new treatment methods can be implemented,” says Gogulski.
About this TMS and depression research news
Author: Aino Pekkarinen
Source: University of Helsinki
Contact:Aino Pekkarinen – University of Helsinki
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Mapping cortical excitability in the human dorsolateral prefrontal cortex” by Juha Gogulski et al. Clinical Neurophysiology
Abstract
Mapping cortical excitability in the human dorsolateral prefrontal cortex
Background
Transcranial magnetic stimulation (TMS) to the dorsolateral prefrontal cortex (dlPFC) is an effective treatment for depression, but the neural effects after TMS remains unclear. TMS paired with electroencephalography (TMS-EEG) can causally probe these neural effects. Nonetheless, variability in single pulse TMS-evoked potentials (TEPs) across dlPFC subregions, and potential artifact induced by muscle activation, necessitate detailed mapping for accurate treatment monitoring.
Objective
To characterize early TEPs anatomically and temporally (20–50 ms) close to the TMS pulse (EL-TEPs), as well as associated muscle artifacts (
Methods
In 16 healthy participants, we applied single-pulse TMS to six targets within the dlPFC at two coil angles and measured EEG responses.
Results
Stimulation location significantly influenced observed EL-TEPs, with posterior and medial targets yielding larger EL-TEPs. Regions with high EL-TEP amplitude had less muscle artifact, and vice versa. The best group-level target yielded 102% larger EL-TEP responses compared to other dlPFC targets. Optimal dlPFC target differed across subjects, suggesting that a personalized targeting approach might boost the EL-TEP by an additional 36%.
Significance
EL-TEPs can be probed without significant muscle-related confounds in posterior-medial regions of the dlPFC. The identification of an optimal group-level target and the potential for further refinement through personalized targeting hold significant implications for optimizing depression treatment protocols.
Dr. Debi Johnson is a medical expert and health journalist dedicated to promoting well-being. With a background in medicine, she offers evidence-based insights into health trends and wellness practices. Beyond her reporting, Dr. Debi enjoys hiking, yoga, and empowering others to lead healthier lives.
